Electromed (NYSE:ELMD) Director Kathleen Skarvan Sells 40,000 Shares

Electromed, Inc. (NYSE:ELMD) Director Kathleen Skarvan sold 40,000 shares of the company’s stock in a transaction on Friday, May 15th. The stock was sold at an average price of $35.48, for a total value of $1,419,200.00. Following the transaction, the director directly owned 35,622 shares in the company, valued at approximately $1,263,868.56. This represents a 52.89% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Electromed Stock Up 0.3%

NYSE:ELMD traded up $0.13 during trading hours on Tuesday, hitting $38.37. 66,918 shares of the stock were exchanged, compared to its average volume of 60,955. The company’s 50 day moving average is $25.66 and its two-hundred day moving average is $26.50. Electromed, Inc. has a twelve month low of $17.73 and a twelve month high of $39.25. The company has a market capitalization of $317.70 million, a P/E ratio of 51.16 and a beta of 0.39.

Institutional Trading of Electromed

Hedge funds and other institutional investors have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new stake in shares of Electromed in the fourth quarter valued at about $29,000. Thurston Springer Miller Herd & Titak Inc. bought a new position in Electromed during the fourth quarter worth about $43,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Electromed during the second quarter worth about $83,000. SG Americas Securities LLC bought a new position in Electromed during the fourth quarter worth about $114,000. Finally, New York State Common Retirement Fund bought a new position in Electromed during the second quarter worth about $103,000. Institutional investors and hedge funds own 40.82% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ELMD. B. Riley Financial increased their price target on Electromed from $38.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, May 13th. Roth Mkm reissued a “buy” rating and issued a $38.00 price target on shares of Electromed in a research note on Wednesday, February 11th. Finally, Zacks Research raised Electromed from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, May 13th. One analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $37.50.

Electromed Company Profile

Electromed Inc (NYSE: ELMD) develops and manufactures sleep therapy products designed to support individuals with breathing disorders such as obstructive sleep apnea. The company’s core business activities include the design, production and distribution of continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) accessories. Electromed’s focus on supplying both disposable and reusable components allows durable medical equipment providers to offer comprehensive therapy solutions to patients.

The company’s product portfolio encompasses masks, mask cushions, headgear, tubing, filters and humidification components.